Lighthouse Investment Partners LLC Buys Shares of 11,000 DaVita Inc. (NYSE:DVA)

Lighthouse Investment Partners LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $1,645,000.

A number of other hedge funds have also made changes to their positions in DVA. SBI Securities Co. Ltd. acquired a new position in shares of DaVita during the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC increased its holdings in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita in the fourth quarter valued at approximately $55,000. Venturi Wealth Management LLC increased its holdings in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after purchasing an additional 152 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after purchasing an additional 131 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the subject of several recent research reports. StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Trading Down 0.3%

DVA opened at $143.98 on Wednesday. DaVita Inc. has a 52 week low of $131.44 and a 52 week high of $179.60. The business has a fifty day simple moving average of $146.00 and a 200-day simple moving average of $153.67. The firm has a market cap of $11.07 billion, a P/E ratio of 13.41, a P/E/G ratio of 1.07 and a beta of 1.14. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. DaVita’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business posted $2.26 earnings per share. On average, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.